Moderna (MRNA) Depreciation & Amortization (CF) (2018 - 2023)

Moderna (MRNA) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $78.0 million the latest figure, recorded in Q1 2023.

• On a quarterly basis, Depreciation & Amortization (CF) fell 1.27% year-over-year to $78.0 million in Q1 2023; TTM through Dec 2023 was $78.0 million, a 77.59% decrease from a year earlier, with the FY2022 full-year figure at $348.0 million, up 50.0% from the prior year.
• Depreciation & Amortization (CF) was $78.0 million for Q1 2023 at Moderna, down from $80.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $113.0 million in Q3 2022 and troughed at $7.0 million in Q1 2020.
• A 5-year average of $42.3 million and a median of $15.0 million in 2021 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) decreased 21.82% in 2020 and soared 1014.29% in 2021, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $9.0 million in 2019, then declined by 21.82% to $7.0 million in 2020, then soared by 1014.29% to $78.0 million in 2021, then gained by 2.56% to $80.0 million in 2022, then declined by 2.5% to $78.0 million in 2023.
• The last three Depreciation & Amortization (CF) figures came in at $78.0 million (Q1 2023), $80.0 million (Q4 2022), and $113.0 million (Q3 2022), per Business Quant data.